<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34161904</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1532-2688</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>91</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Seizure</Title>
          <ISOAbbreviation>Seizure</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study.</ArticleTitle>
        <Pagination>
          <StartPage>159</StartPage>
          <EndPage>166</EndPage>
          <MedlinePgn>159-166</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.seizure.2021.05.025</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1059-1311(21)00183-7</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To retrospectively investigate the prevalence, demography, antiseizure medication (ASM) usage, healthcare resource utilization (HCRU), and mortality of patients with Lennox-Gastaut syndrome (LGS) in primary and secondary care in the UK.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Patients with confirmed LGS were anonymously identified from the UK Clinical Practice Research Datalink (CPRD) GOLD database (01/01/1987-31/1b0/2018) using the LGS Read Code (F250500). Probable LGS was identified using the International Classification of Diseases-10/Read Code for epilepsy (Hospital Episode Statistics [HES]/CPRD) plus rufinamide prescription. Period prevalence was calculated based on patients enrolled in CPRD GOLD and alive in 2017. CPRD data were linked to HES to calculate HCRU, and to the Office for National Statistics mortality registry.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Period prevalence of LGS was 0.578/10,000 (n = 180), with 74 and 106 patients identified with confirmed (0.289/10,000) and probable LGS (0.420/10,000). Mean (max) ASM usage was ~1 (3) per year. In confirmed LGS, valproate (72%), lamotrigine (69%), and clobazam (66%) were the most commonly prescribed ASMs. HCRU (per patient-year) was similar in confirmed and probable LGS and mostly consisted of primary care general practitioner consultations (4-6), outpatient visits (5-10), inpatient admissions (1-4), and A&amp;E visits (1). During the follow-up period, 18 patients died with crude mortality rates of 6.12 (confirmed LGS) and 4.17 (probable LGS) deaths per 1000 person-years.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Prevalence of LGS appears low in the UK. The similarly high HCRU and mortality rates in confirmed and probable LGS support the validity and specificity of the probable LGS algorithm and high burden of LGS.</AbstractText>
          <CopyrightInformation>Copyright © 2021. Published by Elsevier Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chin</LastName>
            <ForeName>Richard F M</ForeName>
            <Initials>RFM</Initials>
            <AffiliationInfo>
              <Affiliation>Muir Maxwell Epilepsy Centre, Child Life and Health, University of Edinburgh, Royal Hospital for Children and Young People, 50 Little France Crescent, Edinburgh BioQuarter, Edinburgh, EH16 4TJ, UK. Electronic address: rchin@exseed.ed.ac.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pickrell</LastName>
            <ForeName>W Owen</ForeName>
            <Initials>WO</Initials>
            <AffiliationInfo>
              <Affiliation>Neurology and Molecular Neuroscience Group, Institute of Life Science, Swansea University Medical School, Swansea University, Swansea, SA2 8PP, UK; Neurology Department, Morriston Hospital, Swansea Bay University Health Board, Swansea, SA6 6NL, UK. Electronic address: w.o.pickrell@swansea.ac.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guelfucci</LastName>
            <ForeName>Florent</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Value, Access &amp; HEOR, Commercial Advisory Group, Syneos Health, 41/45 Boulevard Romain Rolland, 92120 Montrouge, Paris, France. Electronic address: florent.guelfucci@syneoshealth.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martin</LastName>
            <ForeName>Monique</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Evidence Synthesis, Modeling, Communications, Evidera, The Ark, 201 Talgarth Road, London W6 8BJ, UK. Electronic address: martinmoniq@googlemail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Holland</LastName>
            <ForeName>Rowena</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Market Access and Health Economics and Outcomes Research, GW Pharma Ltd, 1 Cavendish Pl, Marylebone, London W1G 0QF, UK. Electronic address: RHolland@gwpharm.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Seizure</MedlineTA>
        <NlmUniqueID>9306979</NlmUniqueID>
        <ISSNLinking>1059-1311</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065768" MajorTopicYN="Y">Lennox Gastaut Syndrome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Antiseizure medication</Keyword>
        <Keyword MajorTopicYN="N">Clinical Practice Research Datalink</Keyword>
        <Keyword MajorTopicYN="N">Healthcare resource utilization</Keyword>
        <Keyword MajorTopicYN="N">Lennox-Gastaut syndrome</Keyword>
        <Keyword MajorTopicYN="N">Prevalence</Keyword>
        <Keyword MajorTopicYN="N">Read Code</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>23</Day>
          <Hour>20</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34161904</ArticleId>
        <ArticleId IdType="doi">10.1016/j.seizure.2021.05.025</ArticleId>
        <ArticleId IdType="pii">S1059-1311(21)00183-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
